Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) have been assigned an average recommendation of “Buy” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $81.29.

GPCR has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research report on Thursday, December 19th. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target for the company. Finally, JMP Securities restated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th.

Structure Therapeutics Stock Performance

GPCR opened at $27.40 on Monday. The stock has a market capitalization of $1.57 billion, a PE ratio of -37.03 and a beta of -2.76. Structure Therapeutics has a one year low of $23.50 and a one year high of $62.74. The business’s 50 day moving average price is $29.32 and its 200 day moving average price is $34.99.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Bank of Montreal Can acquired a new position in shares of Structure Therapeutics in the second quarter worth $1,064,000. JPMorgan Chase & Co. boosted its holdings in Structure Therapeutics by 302.3% in the third quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock valued at $1,489,000 after purchasing an additional 25,500 shares during the period. Vestal Point Capital LP grew its stake in Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares in the last quarter. abrdn plc increased its holdings in Structure Therapeutics by 132.7% during the 3rd quarter. abrdn plc now owns 217,083 shares of the company’s stock worth $9,528,000 after purchasing an additional 123,789 shares during the period. Finally, Barclays PLC raised its position in Structure Therapeutics by 64.5% in the 3rd quarter. Barclays PLC now owns 81,138 shares of the company’s stock valued at $3,562,000 after purchasing an additional 31,815 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.